Rheumatology Unit, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Solna, Stockholm, Sweden.
Ann Rheum Dis. 2010 Dec;69(12):2062-6. doi: 10.1136/ard.2010.142109.
Prevention of disease can in principle be accomplished by identification of environmental and/or lifestyle risk and protective factors followed by public health measures (such as for smoking and lung cancer), or by modification of the individual's reactions to disease-inducing factors (such as in vaccinations against microbes). This review discusses both options based on emerging understanding of aetiologies in inflammatory rheumatic diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The major current opportunity for public health-based prevention lies in avoiding smoking. In RA, recent studies have calculated that, in Sweden (a country characterised by a low frequency of smoking), 20% of all RA cases and 33% of all cases of ACPA-positive RA would not have occurred in a smoke-free society. Smoking is also a major risk factor for SLE but no population attribution is yet available. New avenues for individualised and biology-based prevention are provided by the demonstration that several autoimmune rheumatic diseases are preceded by emergence of subclinical autoimmunity followed by laboratory-based signs of inflammation and finally overt disease. Examples of this process are provided from studies of autoimmunity to citrullinated proteins (in RA), to dsDNA (in SLE in general) and to Ro52 epitopes (in the case of neonatal heart block). The recognition of this sequence of events provides opportunities to intervene specifically and potentially curatively before onset of full-blown disease. Such prevention can be accomplished by modification of inciting antigens (environment), by modification of immunity (more or less specific immunomodulation) or by modification of specific gene functions. In all cases, prevention will be different in different subsets of disease and differ at different time points of disease development. Thus, the road map towards prevention of autoimmune rheumatic diseases includes increased understanding of how genes, environment and immunity interact.
疾病预防原则上可以通过确定环境和/或生活方式风险和保护因素,然后采取公共卫生措施(如针对吸烟和肺癌),或者通过改变个体对致病因素的反应(如针对微生物的疫苗接种)来实现。本综述根据炎症性风湿性疾病(如类风湿关节炎 (RA) 和系统性红斑狼疮 (SLE))病因学的新认识,讨论了这两种选择。基于公共卫生的预防的主要当前机会在于避免吸烟。在 RA 中,最近的研究计算出,在瑞典(一个吸烟频率低的国家),如果没有吸烟,所有 RA 病例中有 20%和所有 ACPA 阳性 RA 病例中有 33%不会发生。吸烟也是 SLE 的主要危险因素,但目前尚无人群归因。通过证明几种自身免疫性风湿性疾病在出现亚临床自身免疫后,然后出现实验室炎症标志物,最后出现显性疾病,为个体化和基于生物学的预防提供了新途径。自身免疫对瓜氨酸化蛋白(在 RA 中)、dsDNA(一般在 SLE 中)和 Ro52 表位(在新生儿心脏阻滞的情况下)的研究提供了这种过程的例子。认识到这一事件序列提供了在全面发病前进行特异性和潜在治疗性干预的机会。这种预防可以通过修饰激发抗原(环境)、修饰免疫(或多或少的特异性免疫调节)或修饰特定基因功能来实现。在所有情况下,预防在疾病的不同亚组中会有所不同,并且在疾病发展的不同时间点也会有所不同。因此,预防自身免疫性风湿性疾病的路线图包括增加对基因、环境和免疫相互作用的理解。